EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Arcus Biosciences's enterprise value is $591.7 Mil.
Arcus Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $117.0 Mil. Therefore, Arcus Biosciences's EV-to-Revenue for today is 5.06.
The historical rank and industry rank for Arcus Biosciences's EV-to-Revenue or its related term are showing as below:
RCUS'
s EV-to-Revenue Range Over the Past 10 Years
Min: -61.6 Med: 13.09 Max: 565.73
Current: 5.06
During the past 8 years, the highest EV-to-Revenue of Arcus Biosciences was 565.73. The lowest was -61.60. And the median was 13.09.
RCUS's EV-to-Revenue is ranked better than 59.83% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs RCUS: 5.06
The historical data trend for Arcus Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arcus Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Arcus Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's EV-to-Revenue falls into.
Arcus Biosciences's current Enterprise Value is $591.7 Mil.
Arcus Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $117.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences's share price for today is $15.55.
Arcus Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.58.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcus Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Arcus Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcus Biosciences (Arcus Biosciences) Business Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCUS has been successfully added to your 